- INTERCEPT-T2D aims to identify high-risk Type 2 Diabetes patients by investigating the role of inflammation in the development of complications.
Inflammatory markers should be used in diabetes medical care to refine T2D associated phenotypes
The overall concept of INTERCEPT-T2D is to establish whether an inflammatory-mediated profile contributes to the onset of Type 2 Diabetes (T2D) complications, thus enabling the identification of patients most at risk of complications and the design of personalized prevention measures.
The project
in numbers
0
Countries
0
Partners
0
Years
0
M€
EU contribution
Immunity Rev Drucker_Donath 25 Donath, M. Y., & Drucker, D. J. (2025). Obesity, diabetes, and inflammation : Pathophysiology and clinical implications. Immunity. https://doi.org/10.1016/j.immuni.2025.09.011
FEBS organized the Spetses Course where early career scientists explored functional genomics and its impact on major metabolic diseases
This Phase 2 randomized study is designed to evaluate dapansutrile’s efficacy and safety in approximately 300 patients with elevated blood glucose, systemic inflammation and at risk for complications of diabetes, despite use of standard-of-care anti-diabetic therapy
